SOCS domain targets ECM assembly in lung fibroblasts and experimental lung fibrosis
Carina Magdaleno, Daniel J. TschumperliniD, Narendiran RajasekaraniD, Archana VaradarajiD
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal disease defined by a progressive decline in lung function due to scarring and accumulation of extracellular matrix (ECM) proteins. The SOCS (Suppressor Of Cytokine Signaling) domain is a 40 amino acid conserved domain known to form a functional ubiquitin ligase complex targeting the Von Hippel Lindau (VHL) protein for proteasomal degradation. Here we show that the SOCS conserved domain operates as a molecular tool, to disrupt collagen and fibronectin fibrils in the ECM associated with fibrotic lung myofibroblasts. Our results demonstrate that fibroblasts differentiated using TGF{beta}, followed by transduction with the SOCS domain, exhibit significantly reduced levels of the contractile myofibroblast-marker, -SMA. Furthermore, in support of its role to retard differentiation, we find that lung fibroblasts expressing the SOCS domain present with significantly reduced levels of -SMA and fibrillar fibronectin after differentiation with TGF{beta}. We show that adenoviral delivery of the SOCS domain in the fibrotic phase of experimental lung fibrosis in mice, significantly reduces collagen accumulation in disease lungs. These data underscore a novel function for the SOCS domain and its potential in ameliorating pathologic matrix deposition in lung fibroblasts and experimental lung fibrosis.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 5
- FWCI
- 1.36
- Field percentile
- top 22%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SRC-mediated and TKS5-enabled podosome formation is an inherent property of IPF fibroblasts, promoting ECM invasion and pulmonary fibrosis
Ilianna Barbayianni, Paraskevi Kanellopoulou, … Vassilis Aidinis·bioRxiv·Jan 25, 2023
- Loss of Fas-signaling in pro-fibrotic fibroblasts impairs homeostatic fibrosis resolution and promotes persistent pulmonary fibrosis
E. F. Redente, S. Chakraborty, … D. W. H. Riches·bioRxiv·Aug 18, 2020
- The IPF fibroblastic focus is an active collagen biosynthesis factory embedded in a distinct extracellular matrix
J. A. Herrera, L. Dingle, … M. A. Schwartz·bioRxiv·Nov 6, 2021
- Myeloid HIF-1α Sustains Hypoxic Fibrotic Fronts and Drives Pulmonary Fibrosis
Yuanyi Wei, Christopher M. Bailey, … Yin Wang·bioRxiv·Mar 11, 2026
- Combined antagonism of Oncostatin M (OSM) and Interleukin 6 (IL-6) provides both anti-fibrotic and anti-inflammatory benefit in pulmonary fibrosis
Rojo A. Ratsimandresy, Emma Doran, … Mark S. Wilson·bioRxiv·Jan 13, 2026
- Targeting Lysyl oxidase-like 2 in Idiopathic Pulmonary Fibrosis
M. S. Espindola, D. M. Habiel, … C. M. Hogaboam·FibrosisPeer-reviewed·Jan 1, 2023